Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges
- PMID: 35074934
- PMCID: PMC8975074
- DOI: 10.1681/ASN.2021060771
Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges
Abstract
Background: Data from the PEXIVAS trial challenged the role of plasma exchange (PLEX) in ANCA-associated vasculitides (AAV). We aimed to describe kidney biopsy from patients with AAV treated with PLEX, evaluate whether histopathologic findings could predict kidney function, and identify which patients would most benefit from PLEX.
Methods: We performed a multicenter, retrospective study on 188 patients with AAV and AKI treated with PLEX and 237 not treated with PLEX. The primary outcome was mortality or KRT at 12 months (M12).
Results: No significant benefit of PLEX for the primary outcome was found. To identify patients benefitting from PLEX, we developed a model predicting the average treatment effect of PLEX for an individual depending on covariables. Using the prediction model, 223 patients had a better predicted outcome with PLEX than without PLEX, and 177 of them had >5% increased predicted probability with PLEX compared with without PLEX of being alive and free from KRT at M12, which defined the PLEX-recommended group. Risk difference for death or KRT at M12 was significantly lower with PLEX in the PLEX-recommended group (-15.9%; 95% CI, -29.4 to -2.5) compared with the PLEX not recommended group (-4.8%; 95% CI, 14.9 to 5.3). Microscopic polyangiitis, MPO-ANCA, higher serum creatinine, crescentic and sclerotic classes, and higher Brix score were more frequent in the PLEX-recommended group. An easy to use score identified patients who would benefit from PLEX. The average treatment effect of PLEX for those with recommended treatment corresponded to an absolute risk reduction for death or KRT at M12 of 24.6%.
Conclusions: PLEX was not associated with a better primary outcome in the whole study population, but we identified a subset of patients who could benefit from PLEX. However, these findings must be validated before utilized in clinical decision making.
Keywords: acute kidney injury; anti-neutrophil cytoplasmic antibody-associated vasculitis; kidney biopsy; plasma exchange.
Copyright © 2022 by the American Society of Nephrology.
Figures


Comment in
-
Plasma Exchange in ANCA-Associated Vasculitis: For Whom (If Any)?J Am Soc Nephrol. 2022 Mar;33(3):465-466. doi: 10.1681/ASN.2021121550. Epub 2022 Jan 24. J Am Soc Nephrol. 2022. PMID: 35074935 Free PMC article. No abstract available.
-
Authors' Reply: Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange.J Am Soc Nephrol. 2022 Jun;33(6):1224-1225. doi: 10.1681/ASN.2022030269. Epub 2022 Apr 11. J Am Soc Nephrol. 2022. PMID: 35410877 Free PMC article. No abstract available.
-
Kidney Histopathology in ANCA-Associated Vasculitides Treated with Plasma Exchange.J Am Soc Nephrol. 2022 Jun;33(6):1223-1224. doi: 10.1681/ASN.2022020164. Epub 2022 Apr 11. J Am Soc Nephrol. 2022. PMID: 35410878 Free PMC article. No abstract available.
References
-
- Berti A, Cornec-Le Gall E, Cornec D, Casal Moura M, Matteson EL, Crowson CS, et al. : Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrol Dial Transplant 34: 1508–1517, 2019 - PMC - PubMed
-
- Millet A, Pederzoli-Ribeil M, Guillevin L, Witko-Sarsat V, Mouthon L: Antineutrophil cytoplasmic antibody-associated vasculitides: Is it time to split up the group? Ann Rheum Dis 72: 1273–1279, 2013 - PubMed
-
- Kronbichler A, Shin JI, Lee KH, Nakagomi D, Quintana LF, Busch M, et al. : Clinical associations of renal involvement in ANCA-associated vasculitis. Autoimmun Rev 19: 102495, 2020 - PubMed
-
- Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. ; European Vasculitis Study Group : Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 18: 2180–2188, 2007 - PubMed
-
- Walsh M, Casian A, Flossmann O, Westman K, Höglund P, Pusey C, et al. ; European Vasculitis Study Group (EUVAS) : Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int 84: 397–402, 2013 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous